X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BMF-219 is an investigational, orally bioavailable, novel covalent menin inhibitor. It is being evaluated for the treatment of type 1 diabetes mellitus.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
BMF-219 is an oral, Menin inhibitor small molecule drug which is under phase 1/2 clinical development for the treatment of Diabetes Mellitus, Type 1.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
BMF-219 is a menin inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of diabetes mellitus, type 1 via oral administration.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Biomea intends to use the net proceeds to fund the continued clinical development of BMF-219, an orally bioavailable, potent and selective covalent inhibitor of menin, for the treatment of patients with liquid and solid tumors, as well as patients with type 2 diabetes.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $172.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 13, 2023
Details:
The net offering will be used to fund the continued clinical development of BMF-219, an orally bioavailable, potent and selective covalent inhibitor of menin, for the treatment of patients with liquid and solid tumors, as well as patients with type 2 diabetes.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor, it blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
BMF-219 an oral investigational covalent menin inhibitor. Optimized covalent inhibitors can provide better inhibition and tolerance than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, and MM patients.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
In animal models, BMF-219 has shown a very unique profile in preserving, reactivating and regenerating beta cells. BMF-219 was designed to specifically inhibit menin.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
BMF-219 is a potential first-in-class, covalent menin inhibitor. Beta cell loss is a critical component of the etiology and pathogenesis of type 1 and type 2 diabetes; menin is thought to function as the brakes on beta cell recovery in the pancreas.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
BMF-219, an oral covalent menin inhibitor, shows powerful cell-killing activity as a novel, first-in-class single agent against CLL patient samples, representing a broad spectrum of mutational profiles, including those with poor prognostic mutations.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in a preclinical animal model, driving an improvement in glycemic control and insulin sensitivity.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
BMF-219 showed prolonged glycemic control in two standard diabetes animal models, the Zucker Diabetic Fatty (ZDF) and Streptozotocin-induced (STZ) Rat models, throughout the dosing period and, additionally, glycemic control was maintained after the dosing period ended.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2022
Details:
BMF-219, a Biomea covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM)
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Menin acts as a ‘brake’ on beta cell regeneration; inhibiting menin function with BMF-219 may increase beta cell production and function, thereby increasing insulin levels and controlling high glucose levels.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
BMF-219, as a single agent, demonstrated a significant reduction in HbA1C versus liraglutide and strong glucose tolerance and glycemic control. These effects were maintained even after dosing had stopped.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
BMF-219, a covalent menin inhibitor, demonstrated potency across ex vivo CLL tumor models with varying cytogenetic risk profiles and Rai stages, indicating broad activity with over 98% cell lethality in these models.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3 isoforms, potentially making it the most potent inhibitor of its class.
Lead Product(s): BMF-500,BMF-219
Therapeutic Area: Oncology Product Name: BMF-500
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived models ex vivo, including diffuse large B-cell lymphoma and cancer.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
BMF-219 was multi-fold more potent and exerted greater cytotoxicity compared to clinical reversible menin inhibitors in DLBCL patient-derived ex vivo samples and over 99% cell lethality in MM cell lines with RAS mutations as a single agent.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
Biomea plans to initiate a Phase I/II clinical trial of lead menin inhibitor BMF-219 in diabetes in the second half of 2022, subject to submission and clearance of an investigational new drug (IND) application.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022
Details:
Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in lymphoma and multiple myeloma preclinical patient-derived ex vivo models, also demonstrated high potency in various KRAS-mutant cell lines.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Preclinical data of BMF-219 showed that they were able to normalize glucose levels in the majority of animals after just two weeks of treatment and also remarkably displayed activity in both the ZDF Rat and the STZ animal models of type 2 diabetes.
Lead Product(s): BMF-219
Therapeutic Area: Endocrinology Product Name: BMF-219
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
Proceeds from the financing will support Biomea Fusion to bring its irreversible menin inhibitor into the clinic to produce first-in-human data for a variety of tumor types.
Lead Product(s): BMF-219
Therapeutic Area: Oncology Product Name: BMF-219
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cormorant Asset Management
Deal Size: $56.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
